CHAMPIONS ONCOLOGY INC

Company Overview

Champions Oncology (CSBR) is a technology-enabled oncology research organization that monetizes a proprietary TumorBank of ~1,500 patient‑derived xenograft (PDX) models and a Datacenter of multi‑omic and pharmacology datasets via three revenue streams: fee‑for‑service preclinical pharmacology, data licensing/Lumin SaaS subscriptions, and an in‑house drug discovery effort (Corellia and other programs). For FY2025 the company reported ~$56.9M revenue (≈$48.6M pharmacology services) with improving gross margins and positive operating income after execution gains, while R&D spend fell to ~$6.8M and the organization employs ~213 staff with 159 in R&D/lab roles. Commercially it serves global biopharma customers, has a ~35‑person salesforce for data/SaaS, and cites key risks in specimen access, competition, lab/regulatory compliance and the need for capital to support growth.

Executive Compensation Practices

Executive pay is likely structured to align with near‑term commercial metrics (pharmacology bookings‑to‑revenue conversion, data license and Lumin subscription growth, margin improvement) and longer‑term discovery milestones (Corellia progress, TumorBank expansion). As a small-cap biotech/CRO hybrid, compensation will typically include modest base salaries, sales commissions for data/SaaS teams, and equity‑heavy long‑term incentives (options/RSUs) to retain specialized scientific talent; the 10‑K notes stock‑based compensation valued using Black‑Scholes. Recent shifts — lower R&D spend, movement to operating profitability, and tighter cash runway — can drive greater emphasis on revenue‑linked bonuses and conservation of cash‑based pay, while segmented business lines (services vs. SaaS vs. drug discovery) suggest different incentive constructs across divisions.

Insider Trading Considerations

Insiders have routine access to materially sensitive information (bookings conversion, timing of ASC 606 revenue recognition, TOS license deals, subscription renewals, PDX/TumorBank expansions, and Corellia milestones) that can cause sharp stock moves when disclosed; medical/regulatory developments (animal welfare, lab licensure, potential FDA scrutiny) are also potential catalysts. Given a limited cash runway and the possibility of future financings, watch for insider activity ahead of capital raises, dilution events, or milestone disclosures; option exercises and equity grants are likely common and can precede sales. Traders and researchers should monitor blackout windows, 10b5‑1 plan filings and pre‑clearance disclosures, cluster trades around quarter‑end bookings and license announcements, and any sudden shifts in insider selling relative to announced operational or licensing wins.